News from epizyme, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jun 10, 2014, 08:00 ET

Epizyme to Give Oral Presentation on Pre-Clinical Models and Early Clinical Observations of EZH2 Inhibitor EPZ-6438 at ASH Meeting on Lymphoma Biology August 10-13, 2014

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with...

May 28, 2014, 08:00 ET

Epizyme, Inc. to Present at Upcoming Conferences in June

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with...

May 13, 2014, 16:00 ET

Epizyme Announces First Quarter 2014 Financial Results and Provides Corporate Update

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with...

May 07, 2014, 09:00 ET

Epizyme, Inc. to Report First Quarter Financial Results and Provide Corporate Update on May 13, 2014

 Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with...

May 07, 2014, 07:30 ET

Epizyme Initiates Pediatric MLL-r Proof-of-Concept Study for EPZ-5676

 Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with...

May 01, 2014, 08:00 ET

Epizyme, Inc. to Present at Upcoming Conferences in May

 Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with...

Apr 30, 2014, 17:24 ET

Epizyme Nominates Dr. Andrew R. Allen For Election to Board of Directors

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with...

Apr 24, 2014, 08:00 ET

Epizyme Announces Notice of Allowance for U.S. Patent Application Covering Methods of Treatment for Cancers with EZH2 Inhibitors

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with...

Apr 22, 2014, 08:00 ET

Epizyme Achieves Lead Candidate Milestone for Third Target in GSK Collaboration, Receives $4 Million in Milestone and License Payments

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with...

Apr 08, 2014, 07:30 ET

Epizyme Granted Patent Covering Diagnosis and Treatment of Cancers Associated with EZH2 Mutation

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with...

Feb 28, 2014, 08:30 ET

Epizyme, Inc. to Present at 34th Annual Cowen and Company Health Care Conference on March 3, 2014

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with...

Feb 27, 2014, 16:00 ET

Epizyme Announces 2013 Operating and Financial Results and Provides 2014 Guidance

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with...

Feb 27, 2014, 08:00 ET

Epizyme Achieves Lead Candidate Selection Milestone in GSK Collaboration, Earning $2 Million Milestone

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with...

Feb 21, 2014, 08:11 ET

Epizyme Announces Publication of Preclinical Data Demonstrating Clinical Candidate EPZ-6438 as Potent and Selective Inhibitor of EZH2 in Genetically Defined Non-Hodgkin Lymphoma

Epizyme, Inc., (NASDAQ: EPZM) a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with...

Feb 19, 2014, 16:30 ET

Epizyme, Inc. to Report Fourth Quarter and Year-End 2013 Financial Results on February 27, 2014

 Epizyme, Inc., (NASDAQ: EPZM) a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with...

Feb 11, 2014, 08:00 ET

Epizyme Announces Exercise of Underwriters' Option to Purchase Additional Shares of Common Stock

 Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company that is discovering, developing and planning to commercialize...

Feb 07, 2014, 08:00 ET

Epizyme, Inc. to Present at Upcoming Conferences in February

 Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with...

Feb 05, 2014, 08:00 ET

Epizyme Announces Pricing of Public Offering of Common Stock

 Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company that is discovering, developing and planning to commercialize...

Feb 03, 2014, 06:51 ET

Epizyme Announces Proposed Public Offering of Common Stock

 Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company that is discovering, developing and planning to commercialize...

Jan 06, 2014, 17:29 ET

Epizyme and Celgene Advance EPZ-5676 DOT1L Inhibitor Clinical Program to Benefit Cancer Patients with Acute Leukemias, Achieving $25 Million Clinical Proof of Concept Milestone

– Epizyme Also Achieves $4 Million Development Candidate Milestone with GSK – – 2013 End-of-Year Cash Guidance Increased...